# Evolution of myeloid-mediated immunotherapy resistance in prostate cancer

*PRI Rank #11 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-11*

| Field | Value |
| --- | --- |
| Rank | #11 |
| 18m citations | 136 |
| Journal | Nature |
| Year | 2024 |
| DOI | 10.1038/s41586-024-08290-3 |
| Corresponding authors | Lawrence Fong |
| Institution | University of California, San Francisco, United States |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1038/s41586-024-08290-3](https://doi.org/10.1038/s41586-024-08290-3)

## Topics

Metastatic castration-resistant prostate cancer · Metastatic castration-resistant prostate cancer · immune checkpoint inhibitors · SPP1hi tumor-associated macrophages · SPP1hi tumor-associated macrophages · CSF1R blockade · single-cell analysis · CD8+ T cell suppression · adenosine signaling · adenosine A2A receptors · A2AR inhibition · ciforadenant · PD-1 inhibition · PD-L1 inhibition · atezolizumab · immunotherapy resistance · myeloid-mediated immunosuppression · syngeneic mouse models · ICI resistance mechanisms

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```